GraftAssureCore
Commercial- Indications
- Transplant monitoring
Company intelligence / Profile preview
Insight Molecular Diagnostics (iMDx) specializes in blood-based assays for cancer and transplant monitoring. It offers clinical and research-use-only tests, including the commercially available DetermaRx, DetermaIO, research kits (e.g., GraftAssureIQ), and is advancing GraftAssureDx toward FDA submission with initial revenue already reported. Its platform enables earlier detection of cancer progression and non-invasive transplant rejection monitoring, with strategic collaborations and positive clinical validation.[1][2][3][6][7]
5 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Insight Molecular Diagnostics.